Eris Lifesciences is all set to launch generic Semaglutide under the brand ‘SUNDAE’ in India on March 21, 2026. The company is introducing SUNDAE in multi-dose vial formats at highly accessible pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. This launch significantly improves affordability, bringing effective GLP-1 therapy within reach for nearly 70% of India’s diabetes patient population. The company also plans to further enhance patient convenience and adoption with the introduction of a pen-device version in April priced at MRP of Rs 4,000, Rs 4,200 and Rs 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively.
Semaglutide, a GLP-1 receptor agonist, has emerged as a transformative therapy for Type 2 diabetes and weight management, driven by strong outcomes in glycemic control and weight reduction. With India’s rapidly growing diabetic population and rising awareness of obesity, GLP-1 therapies present a significant growth opportunity.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: